Literature DB >> 10509562

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

L Profit1, V A Eagling, D J Back.   

Abstract

OBJECTIVES: To determine the effect of the protease inhibitors ritonavir, nelfinavir and indinavir on the P-glycoprotein (P-gp)-mediated transport of saquinavir in Caco-2 cell monolayers. To study the modulation of P-gp function in human lymphocytes by saquinavir, ritonavir, nelfinavir and indinavir.
METHODS: We examined the effect of the protease inhibitors on P-gp function in human lymphocytes by using Rhodamine 123 (Rh 123; a fluorescent substrate of P-gp) by flow cytometry. Efflux of Rh 123 correlates with P-gp function and inhibition of P-gp results in dye retention. Verapamil, a P-gp modulator and inhibitor of active transport at 4 degrees C was used as a positive control. The transport of [14C]saquinavir (1 microM) across Caco-2 cell monolayers was investigated, alone and in the presence of verapamil and ketoconazole (500 microM) and the protease inhibitors at 100 microM. Caco-2 cells are an in vitro model of the intestinal epithelium that is widely used for the study of P-gp function. The transport of saquinavir was determined in both the apical to basolateral (AP-BL) and basolateral to apical (BL-AP) directions.
RESULTS: Saquinavir and ritonavir (10 microM) markedly inhibited Rh 123 efflux with an increase in fluorescence intensity similar to that obtained with verapamil. A small but statistically significant increase in fluorescence intensity was observed with nelfinavir; however indinavir did not modulate Rh 123 efflux. In Caco-2 cells the apparent permeability coefficient for BL-AP efflux of saquinavir exceeded that for AP-BL efflux by a factor of 26: this is indicative of an active efflux pump. Known P-gp modulators caused a decrease in BL-AP efflux and an increase in AP-BL transport. The protease inhibitors displayed some P-gp modulation with ritonavir having the most potent effect.
CONCLUSIONS: We have demonstrated that saquinavir is a substrate for P-gp and that ritonavir, nelfinavir and indinavir modulate P-gp function in both human lymphocytes and Caco-2 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509562     DOI: 10.1097/00002030-199909100-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

Review 1.  The role of therapeutic drug monitoring in treatment of HIV infection.

Authors:  D J Back; S H Khoo; S E Gibbons; C Merry
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.

Authors:  Elke Störmer; Lisa L von Moltke; Michael D Perloff; David J Greenblatt
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

4.  P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.

Authors:  Chiara Agrati; Fabrizio Poccia; Simone Topino; Pasquale Narciso; Cinzia Selva; Leopoldo Paolo Pucillo; Gianpiero D'Offizi; Guido Antonelli; Francesca Bellomi; Ombretta Turriziani; Federica Bambacioni
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 5.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 6.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of darunavir.

Authors:  Michael Rittweger; Keikawus Arastéh
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Authors:  Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

10.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.